Aesthetics Biomedical® Inc. Announces Issuance Of Its Second U.S. Patent For “Biologic Preserving Composition And Methods Of Use”

Share Article

Aesthetics Biomedical® Inc. Announces Issuance Of Its Second U.S. Patent For “Biologic Preserving Composition And Methods Of Use”

Aesthetics Biomedical® Inc., a regenerative medicine company committed to the development and distribution of innovative aesthetic devices and skincare products for the global market, proudly announces the issuance of its second US Patent for Biologic Preserving Composition and Methods of Use. The January 5th, 2021 issued patent covers topical compositions for combining biologics with skincare.

This announcement comes only weeks after publication of Aesthetics Biomedical’s (ABM) second paper on SoME® Skincare, demonstrating clinical efficacy following 120 days of topical treatment. (J Drugs & Dermatology Vol 19, Dec 2020) SoME® Skincare is the first in its class, allowing the utilization of personalized autologous platelet rich plasma (PRP) in a topical skincare product for 90 days of home use. An earlier controlled, double blinded, eight-week study demonstrated, tolerability and significant efficacy of the topical product for facial rejuvenation. (J Cosmetic Dermatol Vol 18, Issue 5, 2019). The patented cosmetic base formulation serves as a “chassis”, platform technology, from which other upscale functional topical products can be developed for various skin conditions.

“With ABM’s issuance of a second patent that covers biologic use within a topical product along with the recent publication that offers new insights relating to the stability and use of PRP in the clinical setting, clearly demonstrates that ABM is solidifying themselves as a key player in personalized topicals,” says Shaun Wootten, Director of Research & Development at Aesthetics Biomedical® Inc. Wootten further states that “ABM has a pipeline of other personalized skincare products that can incorporate PRP and other autologous factors that will be available to the plastic surgery, dermatology, medical spa, and cosmetic businesses.”

“Aesthetics Biomedical® remains focused on developing the required basic and clinical research to successfully commercialize these innovative products. The issuance of this second patent helps solidify the company’s proprietary position, providing for a product pipeline based on natural, autologous growth factors for skin and haircare. We will use our creativity to provide the aesthetic physician community with the most innovative, safe and efficacious products," says MaryAnn Guerra, President and CEO.

The field of aesthetic medicine continues to grow at an exponential rate. Energy devices, physician-dispensed skincare, and injectables will continue to play a critical role as the field continues to look for minimally-invasive safe, precise, products to treat the effects of the intrinsic/ extrinsic aging process. The incorporation of personalized, natural, autologous factors for prejuvenation and rejuvenation for the face and hair growth provides highly efficacious in-office co- treatments to potentiate the desired aesthetic effect. The new decade will no doubt provide both physicians and patients with a plethora of safe and innovative approaches for aesthetic medicine.

Aesthetics Biomedical® Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical’s innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. Visit or

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sheldon Larson
Aesthetics Biomedical
Like >
Visit website